Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: The ability of endoscopic submucosal dissection (ESD) to resect large early gastric cancers (EGCs) results in the need to treat large artificial gastric ulcers. This study assessed whether the combination therapy of rebamipide plus a proton pump inhibitor (PPI) offered benefits over PPI monotherapy. Methods: In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66). The Scar stage (S stage) ratio after treatment was compared, and factors independently associated with ulcer healing were identified by using multivariate analyses. Results: The S stage rates at 4 and 8 weeks were similar in the two groups, even in the subgroups of patients with large amounts of tissue resected and regardless of CYP2C19 genotype. Independent factors for ulcer healing were circumferential location of the tumor and resected tissue size; the type of treatment did not affect ulcer healing. Conclusions: Combination therapy with rebamipide and PPI had limited benefits compared with PPI monotherapy in the treatment of post-ESD gastric ulcer (UMIN Clinical Trials Registry, UMIN000007435).
Abstract
Background/Aims: The ability of endoscopic submucosal dissection (ESD) to resect large early gastric cancers (EGCs) results in the need to treat large artificial gastric ulcers. This study assessed whether the combination therapy of rebamipide plus a proton pump inhibitor (PPI) offered benefits over PPI monotherapy. Methods: In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66). The Scar stage (S stage) ratio after treatment was compared, and factors independently associated with ulcer healing were identified by using multivariate analyses. Results: The S stage rates at 4 and 8 weeks were similar in the two groups, even in the subgroups of patients with large amounts of tissue resected and regardless of CYP2C19 genotype. Independent factors for ulcer healing were circumferential location of the tumor and resected tissue size; the type of treatment did not affect ulcer healing. Conclusions: Combination therapy with rebamipide and PPI had limited benefits compared with PPI monotherapy in the treatment of post-ESD gastric ulcer (UMIN Clinical Trials Registry, UMIN000007435).
참고문헌 (18)
- Gotoda T, "Endoscopic resection of early gastric cancer", Gastric Cancer, 10, pp.1~11 (2007)
- Oda I, "A multicenter retrospective study of endoscopic resection for early gastric cancer", Gastric Cancer, 9, pp.262~270 (2006)
- Gotoda T, "Endoscopic submucosal dissection of early gastric cancer", J Gastroenterol, 41, pp.929~942 (2006)
- Uedo N, "Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial", Am J Gastroenterol, 102, pp.1610~1616 (2007)
- Oh TH, "Degree of healing and healingassociated factors of endoscopic submucosal dissection-induced ulcers after pantoprazole therapy for 4 weeks", Dig Dis Sci, 54, pp.1494~1499 (2009)
- Andersson T, "Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism", Br J Clin Pharmacol, 37, pp.597~604 (1994)
- Katsuki H, "Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects", Eur J Clin Pharmacol, 52, pp.391~396 (1997)
- Horai Y, "Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes", Aliment Pharmacol Ther, 15, pp.793~803 (2001)
- Shirai N, "Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH", Aliment Pharmacol Ther, 15, pp.1929~1937 (2001)
- Kato T, "Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection: a randomized controlled study", J Gastroenterol, 45, pp.285~290 (2010)
- Fujiwara S, "A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection", J Gastroenterol, 46, pp.595~602 (2011)
- Japanese Gastric Cancer Association, "Japanese gastric cancer treatment guidelines 2010 (ver. 3)", Gastric Cancer, 14, pp.113~123 (2011)
- Nakamura K, "Suitability of the expanded indication criteria for the treatment of early gastric cancer by endoscopic submucosal dissection: Japanese multicenter largescale retrospective analysis of short- and long-term outcomes", Scand J Gastroenterol, 50, pp.413~422 (2015)
- Akahoshi K, "Endoscopic submucosal dissection using a grasping-type scissors forceps for early gastric cancers and adenomas", Dig Endosc, 23, pp.24~29 (2011)
- Itaba S, "Low-frequency of bacteremia after endoscopic submucosal dissection of the stomach", Dig Endosc, 23, pp.69~72 (2011)
- Kubota T, "Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population", Clin Pharmacol Ther, 60, pp.661~666 (1996)
- Araki H, "Combination of proton pump inhibitor and rebamipide, a free radical scavenger, promotes artificial ulcer healing after endoscopic submucosal dissection with dissection size >40 mm", J Clin Biochem Nutr, 51, pp.185~188 (2012)
- Shin WG, "Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study", Gastrointest Endosc, 75, pp.739~747 (2012)